Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib neoadjuvant study in germline BRCA-mutated HER2-negative early breast cancer
ChiCTR2400093008Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluzoparib in breast cancer, sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Total pathologic complete response. Started Nov 2024; status: recruiting.
02
Drugs
fluzoparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2400093008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093008.